Clinical Trial Results:
Simvastatin as adjuvant therapy to correct neutrophil dysfunction in older pneumonia patients - a randomised double blind placebo controlled trial
Summary
|
|
EudraCT number |
2012-003343-29 |
Trial protocol |
GB |
Global end of trial date |
30 Dec 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Nov 2019
|
First version publication date |
27 Nov 2019
|
Other versions |
|
Summary report(s) |
Abridged protocol |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
RG_12-179
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University of Birmingham
|
||
Sponsor organisation address |
Edgbaston, Birmingham, United Kingdom, B152TT
|
||
Public contact |
Clinical Trials Coordinator, Queen Elizabeth Hospital Birmingham NHS Trust, 44 01214721311, anita.pye@uhb.nhs.uk
|
||
Scientific contact |
Clinical Trials Coordinator, Queen Elizabeth Hospital Birmingham NHS Trust, 44 01214721311, anita.pye@uhb.nhs.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
06 Mar 2018
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Dec 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Pneumonia (severe lung infection) is one of the commonest causes of death and the death rate has not fallen for many years. Elderly patients are at greater risk of pneumonia and its complications such as sepsis. Usually the immune system works cooperatively to clear infection and prevent organ damage. Neutrophils are cells of the immune system that are critical in clearing bacteria. These cells are the foot soldiers of the immune system and move from the blood into infected tissues/organs to locate and kill the invading bacteria using an arsenal of toxic products. Sepsis occurs when the bodies normally helpful reaction to infection becomes harmful. As part of this process, neutrophils stop working properly, they become less able to clear bacteria and release their toxic products indiscriminately, causing organ damage. Defects in the efficiency of these cells is associated with a poor outcome from pneumonia and sepsis. We have undertaken a pilot study in patients, which
|
||
Protection of trial subjects |
As per EU CTIMP law and under MHRA guidance.
Daily review by research team and safety bloods taken for creatine kinase, liver function tests and renal function, as stipulated in the protocol.
|
||
Background therapy |
Patients were treated as per British Thoracic Society Community acquired pneumonia with the patients physician directing care. Contraindicated drugs were stipulated in protocol inclusion and exclusion criteria. | ||
Evidence for comparator |
This was an additional therapy | ||
Actual start date of recruitment |
07 Jan 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 62
|
||
Worldwide total number of subjects |
62
|
||
EEA total number of subjects |
62
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
8
|
||
From 65 to 84 years |
33
|
||
85 years and over |
21
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Patients were recruited from a secondary care hospital. They were eligible if they met The British Thoracic Society guidelines for community acquired pneumonia, and the 2012 Surviving Sepsis Campaign Guidelines | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Chest radiograph review, bloods and observations. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Within 48 hours of admission (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||
Blinding implementation details |
The randomization sequence was pre-determined by Sharp Clinical Services, designed to provide a 1:1 randomization pattern.
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Statin treatment | ||||||||||||||||||
Arm description |
Simvastatin 80mg OD PO | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Simvastatin
|
||||||||||||||||||
Investigational medicinal product code |
MA - PL0075/0017
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
80mg orally once daily
|
||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||
Arm description |
Placebo tablet | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||
Investigational medicinal product code |
MA10284
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
DBAAe capsule shells filled with Microcrystalline cellulose taken once a day
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Statin treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Simvastatin 80mg OD PO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo tablet | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
All randomised subjects
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All subject data analysed on intention to treat basis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Simvastatin Day 4 - Day 0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All analysis on intention to treat basis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Placebo Day 4 - Day 0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All analysis on intention to treat basis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Statin treatment
|
||
Reporting group description |
Simvastatin 80mg OD PO | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo tablet | ||
Subject analysis set title |
All randomised subjects
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All subject data analysed on intention to treat basis
|
||
Subject analysis set title |
Simvastatin Day 4 - Day 0
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All analysis on intention to treat basis
|
||
Subject analysis set title |
Placebo Day 4 - Day 0
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All analysis on intention to treat basis
|
|
|||||||||||||||||||||
End point title |
Change in fMLP induced NETosis | ||||||||||||||||||||
End point description |
Neutrophil extracellular traps
|
||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
Change from Day 0 to day 4
|
||||||||||||||||||||
|
|||||||||||||||||||||
Attachments |
Change in NETosis |
||||||||||||||||||||
Statistical analysis title |
Change in netosis | ||||||||||||||||||||
Statistical analysis description |
Day 4 - Day 0 results
|
||||||||||||||||||||
Comparison groups |
Simvastatin Day 4 - Day 0 v Placebo Day 4 - Day 0
|
||||||||||||||||||||
Number of subjects included in analysis |
62
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
= 0.034 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Parameter type |
Median difference (final values) | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
90% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
- | ||||||||||||||||||||
upper limit |
- |
|
|||||||||||||
End point title |
Change in neutrophil migration | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 4 - Day 0
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change in chemotaxis | ||||||||||||
Comparison groups |
Simvastatin Day 4 - Day 0 v Placebo Day 4 - Day 0
|
||||||||||||
Number of subjects included in analysis |
62
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.033 | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Systemic neutrophil elastase activity | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 4 - Day 0
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change in neutrophil elastase activity | ||||||||||||
Comparison groups |
Simvastatin Day 4 - Day 0 v Placebo Day 4 - Day 0
|
||||||||||||
Number of subjects included in analysis |
41
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.001 | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Change in SOFA score | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 4 - Day 0
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Change in SOFA score from day 0 to day 4 | ||||||||||||
Comparison groups |
Simvastatin Day 4 - Day 0 v Placebo Day 4 - Day 0
|
||||||||||||
Number of subjects included in analysis |
62
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.026 | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|
|||||||||||||||||
End point title |
Hospitalisation free survival | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Post-hoc
|
||||||||||||||||
End point timeframe |
Analysis of readmission and survival as a composite endpoint at 180-days
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Odds ratio | ||||||||||||||||
Comparison groups |
Placebo Day 4 - Day 0 v Simvastatin Day 4 - Day 0 v All randomised subjects
|
||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||
Analysis specification |
Post-hoc
|
||||||||||||||||
Analysis type |
superiority [1] | ||||||||||||||||
P-value |
= 0.03 | ||||||||||||||||
Method |
Odds ratio | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [1] - Analysis of readmission and survival as a composite endpoint demonstrated a significant increase in hospitalization free survival at both 180-days Odds ratio: 0.45; 95% CI 0.22 to 0.93 |
|
|||||||||||||||||
End point title |
Hospitalisation free survival 365 days | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Post-hoc
|
||||||||||||||||
End point timeframe |
Analysis of readmission and survival as a composite endpoint at 365-days
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Odds ratio for hospitalisation free survival | ||||||||||||||||
Statistical analysis description |
Comparing those on CTIMP to placebo
|
||||||||||||||||
Comparison groups |
Simvastatin Day 4 - Day 0 v Placebo Day 4 - Day 0
|
||||||||||||||||
Number of subjects included in analysis |
62
|
||||||||||||||||
Analysis specification |
Post-hoc
|
||||||||||||||||
Analysis type |
superiority [2] | ||||||||||||||||
P-value |
= 0.03 | ||||||||||||||||
Method |
odds ratio | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [2] - Odds ratio: 0.45, 95% CI 0.22 to 0.90 |
|
|||||||||||||||
Adverse events information
|
|||||||||||||||
Timeframe for reporting adverse events |
All SAEs irrespective of the causal relationship with the trial medications will be reported to the Sponsor within 24 hours of awareness by the investigator.
|
||||||||||||||
Assessment type |
Systematic | ||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||
Dictionary name |
ICD | ||||||||||||||
Dictionary version |
10
|
||||||||||||||
Reporting groups
|
|||||||||||||||
Reporting group title |
Only 1 Adverse event reported
|
||||||||||||||
Reporting group description |
One adverse event- myalgia in the simvastatin arm | ||||||||||||||
|
|||||||||||||||
Frequency threshold for reporting non-serious adverse events: 2% | |||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
01 Dec 2014 |
5 amendments in total. 2 prior to study start (1 of these stipulated by MHRA to add more contraindicated medications).
Last amendment 2014. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/31206313 |